
Toronto Innovation Acceleration Partners
Investments
28Funds
4Partners & Customers
10About Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners (TIAP) specializes in venture building of early-stage health science technologies emerging from our members. Toronto Innovation Acceleration Partners (TIAP) is a member-driven not-for-profit organization which was created in 2008 (at that time under the name "MaRS Innovation") by 13 of Toronto's top universities, institutions and research institutes, plus the MaRS Discovery District as host organization. Its mandate is to bring the members' most promising research breakthroughs to market. In addition to member support, early funding came from the Federal Government through the Centres of Excellence for Commercialization and Research program.

Want to inform investors similar to Toronto Innovation Acceleration Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Toronto Innovation Acceleration Partners News
Jul 12, 2023
News Provided By Share This Article Novel nanotechnology uses natural lipid-based particles to selectively target cancer cells and harness the human body for targeted immune therapy CHICAGO, ILLINOIS, UNITED STATES, July 12, 2023/ EINPresswire.com / -- Nanogenix™, a new biotechnology company launched July 1st out of University Health Network’s (UHN) new ventures pipeline, aims to initiate clinical trials for its novel photo-immune therapy platform to change treatment prospects for cancer patients. UHN is Canada’s leading research hospital and Canada’s medical research commercialization leader. The company’s development was also supported by the Toronto Innovation Acceleration Partners (TIAP). The company’s new class of drug and device combination platform is based on porphysome technology developed by Dr. Gang Zheng, Senior Scientist and Associate Research Director, Princess Margaret Cancer Centre at UHN. Dr. Zheng is also the Scientific Co-Founder at Nanogenix, together with Dr. Brian Wilson, and Michael Valic, both researchers at the Princess Margaret Cancer Centre. Their research focus lies in the development of novel technologies and methods that can be applied to cancer detection/diagnosis, cancer treatment, and image-guided cancer interventions. With an initial focus on skin and pancreatic cancers, the company’s proprietary multifunction platform includes direct therapeutic, diagnostic imaging and drug delivery agents. The technology is based on naturally occurring lipid-based particles (porphysomes) which, when modified, can selectively target cancer cells while preserving normal tissue. The company is targeting mid-late 2024 to initiate Phase I clinical trials of its lead cancer therapeutic. “Nanogenix’s platform uses unique porphysome based nanoparticles to destroy tumour tissue without damaging normal tissue in cancer patients who could otherwise be facing more aggressive treatment options or who may have limited options. We are particularly impressed with recent preclinical findings that this therapy also induces a positive immune response that could synergistically impact the anti-cancer effect. The nanoparticles we’ve developed the Nanogenix platform around are also uniquely flexible to meet a particular clinical need,” says Zheng. “Nanogenix offers a multifunction platform designed to increase quality of life and survival rates in pancreatic cancer. Poised to be less invasive than currently available therapies, the platform already demonstrates significant advancements in cancer cell selectivity and immune response relative to existing therapies in the target disease categories.” says Glenn Kutschera, President and CEO, Nanogenix. “Also, in light of recent preclinical findings, we are very excited about the potential synergies porphysome therapy may have with other immune-oncology agents across multiple indications. We are very impressed with our combined preclinical results to date, and look forward to initiating our phase I clinical trials.” “Congratulations to Nanogenix on their company launch to scale novel nanotechnology therapies invented and de-risked at our Princess Margaret Cancer Centre,” said Mark Taylor, Director, Commercialization, University Health Network. “The new venture model at UHN keeps our patients at the centre and we are thrilled to see this technology taking the next step forward towards having widespread impact on patient lives globally. We are also thrilled that Nanogenix will have a research and development base right here in Toronto, where proximity to our world class research and vibrant life sciences ecosystem creates new opportunities for collaboration that keeps companies in Canada.” “The Nanogenix company launch is very good news as it marks a significant inflection point for the technology. TIAP is excited to continue to support the Nanogenix platform through our Venture Builder Program. This is a prime example of what can be achieved through the combination of stellar research and productive partnering with our members, in this case UHN. We appreciate the financial support provided to projects in our Venture Builder program by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario),” says Parimal Nathwani, President & CEO of TIAP. Nanogenix is now in the process of raising Series A financing in order to advance its platform into human clinical trials. The Nanogenix team is grateful for research and development support via UHN’s Innovation Acceleration Fund, supported by the Princess Margaret Cancer Foundation, which has helped advance the development of its therapeutic platform. About the Nanogenix Management Team: Glenn Kutschera, Chief Executive Officer Glenn has over 25 years of experience in the pharmaceutical industry, most recently 9 years as President of a US based oncology biotechnology company. Paul Sieroslawski, Chief Financial Officer & Chief Operations Officer Paul has over 25 years of experience in financial management, most recently 11 years leading finance and operations at a US based oncology biotechnology company. Working together at a US based biotech company, Paul and Glenn have led multiple clinical programs ranging from preclinical to early stage and phase III trials within oncology. They were instrumental in gaining FDA approval of 6 newly developed PMA/Class III level medical devices, quadrupling the volume of oncology institutions using the company’s FDA approved cancer therapeutic and re-designing and streamlining a complex, multi-faceted cGMP manufacturing process. Paul Sieroslawski
Toronto Innovation Acceleration Partners Investments
28 Investments
Toronto Innovation Acceleration Partners has made 28 investments. Their latest investment was in Radiant Biotherapeutics as part of their Seed VC on April 4, 2023.

Toronto Innovation Acceleration Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/25/2023 | Seed VC | Radiant Biotherapeutics | $5.88M | Yes | 1 | |
9/26/2022 | Seed VC | DAMONA Pharmaceuticals | $5.5M | Yes | Angelini Pharma, Noetic Fund, Toronto Innovation Acceleration Partners, and Undisclosed Investors | 1 |
3/17/2022 | Seed VC - II | MedMe Health | $2.7M | Yes | 4 | |
9/21/2021 | Seed VC | |||||
2/8/2018 | Convertible Note |
Date | 4/25/2023 | 9/26/2022 | 3/17/2022 | 9/21/2021 | 2/8/2018 |
---|---|---|---|---|---|
Round | Seed VC | Seed VC | Seed VC - II | Seed VC | Convertible Note |
Company | Radiant Biotherapeutics | DAMONA Pharmaceuticals | MedMe Health | ||
Amount | $5.88M | $5.5M | $2.7M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Angelini Pharma, Noetic Fund, Toronto Innovation Acceleration Partners, and Undisclosed Investors | ||||
Sources | 1 | 1 | 4 |
Toronto Innovation Acceleration Partners Fund History
4 Fund Histories
Toronto Innovation Acceleration Partners has 4 funds, including MaRS Innovation - Pfizer Translational Research Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/9/2018 | MaRS Innovation - Pfizer Translational Research Fund | $0.63M | 1 | ||
12/12/2014 | MaRS Impact Venture Fund | ||||
3/26/2012 | MaRS Cleantech Fund | ||||
5/31/2011 | GSK-MaRS Innovation Fund |
Closing Date | 4/9/2018 | 12/12/2014 | 3/26/2012 | 5/31/2011 |
---|---|---|---|---|
Fund | MaRS Innovation - Pfizer Translational Research Fund | MaRS Impact Venture Fund | MaRS Cleantech Fund | GSK-MaRS Innovation Fund |
Fund Type | ||||
Status | ||||
Amount | $0.63M | |||
Sources | 1 |
Toronto Innovation Acceleration Partners Partners & Customers
10 Partners and customers
Toronto Innovation Acceleration Partners has 10 strategic partners and customers. Toronto Innovation Acceleration Partners recently partnered with Amgen on September 9, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
9/12/2019 | Partner | United States | TIAP TIAP Announces Strategic Partnership with Amgen - TIAP `` Amgen is enthusiastic about this strategic partnership with TIAP , '' added Francesco Di Marco , Vice President and General Manager of Amgen . | 2 | |
6/19/2018 | Partner | Germany | Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics - Evotec Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics LP . | 1 | |
12/21/2017 | Partner | United States | Schrödinger and MaRS Innovation Announce the Launch of Bright Angel Therapeutics. `` The partnership between Schrödinger and Bright Angel Therapeutics is the fruitful realization of MaRS Innovation 's aim to create important strategic partnerships to better advance our Members ' technologies , '' said Dr. Raphael Hofstein , President and CEO of MaRS Innovation . | 1 | |
11/28/2017 | Partner | ||||
9/14/2017 | Partner |
Date | 9/12/2019 | 6/19/2018 | 12/21/2017 | 11/28/2017 | 9/14/2017 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | Germany | United States | ||
News Snippet | TIAP TIAP Announces Strategic Partnership with Amgen - TIAP `` Amgen is enthusiastic about this strategic partnership with TIAP , '' added Francesco Di Marco , Vice President and General Manager of Amgen . | Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics - Evotec Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics LP . | Schrödinger and MaRS Innovation Announce the Launch of Bright Angel Therapeutics. `` The partnership between Schrödinger and Bright Angel Therapeutics is the fruitful realization of MaRS Innovation 's aim to create important strategic partnerships to better advance our Members ' technologies , '' said Dr. Raphael Hofstein , President and CEO of MaRS Innovation . | ||
Sources | 2 | 1 | 1 |
Toronto Innovation Acceleration Partners Team
2 Team Members
Toronto Innovation Acceleration Partners has 2 team members, including current Chief Executive Officer, President, Parimal Nathwani.
Name | Work History | Title | Status |
---|---|---|---|
Parimal Nathwani | Chief Executive Officer, President | Current | |
Name | Parimal Nathwani | |
---|---|---|
Work History | ||
Title | Chief Executive Officer, President | |
Status | Current |
Compare Toronto Innovation Acceleration Partners to Competitors

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.
J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.

Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.
Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
Informed Medical is an interactive medical information services provider that enables biopharmaceutical companies to market directly to physicians and patients.